US FDA Approves StemCyte Biologics License Application for REGENECYTE Cord Blood Cell Therapy Product

0
519
StemCyte Inc. announced that the US FDA has approved the Biologics License Application for its HPC, Cord Blood product REGENECYTE, a vital cord blood stem cell therapy for transplantation in patients with blood and immune system disorders.
[StemCyte, Inc.]
Press Release